Particle Beam Therapy for Cardiac-Sparing Radiotherapy in Non-Small Cell Lung Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33610267.
- Also identified by DOI 10.1016/j.semradonc.2020.11.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiation therapy plays an integral role in the treatment of all stages of non-small cell lung cancer. Survival outcomes are improving, but radiation therapy remains associated with long-term toxicity. Recently, it has become evident that the heart is an important organ at risk for treatment-related morbidity. In this review, we discuss the hypothesis that particle radiation therapy offers superior dosimetry compared with photon-based treatment, and that this comparative advantage translates into clinically meaningful cardiac toxicity reduction with similar local tumor control. We discuss the evidence in non-small cell lung cancer to date, the ongoing prospective trials that may provide additional insight, and the opportunities to optimally integrate particle therapy into future prospective investigation.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms